DOCSLIB.ORG

REMICADE (Infliximab)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
REMICADE (Infliximab) HIGHLIGHTS OF PRESCRIBING INFORMATION REMICADE is administered by intravenous infusion over a period of not less These highlights do not include all the information needed to use than 2 hours. REMICADE® safely and effectively. See full prescribing information for Crohn’s Disease (2.1) REMICADE. 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adult patients who REMICADE (infliximab) initially respond to treatment may benefit from increasing the dose to 10 Lyophilized Concentrate for Injection, for Intravenous Use mg/kg if they later lose their response. Initial U.S. Approval: 1998 Pediatric Crohn’s Disease (2.2) 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. WARNING: SERIOUS INFECTIONS and MALIGNANCY Ulcerative Colitis (2.3) See full prescribing information for complete boxed warning 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. SERIOUS INFECTIONS Pediatric Ulcerative Colitis (2.4) Increased risk of serious infections leading to hospitalization or 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. death, including tuberculosis (TB), bacterial sepsis, invasive fungal Rheumatoid Arthritis (2.5) infections (such as histoplasmosis) and infections due to other In conjunction with methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every opportunistic pathogens. 8 weeks. Some patients may benefit from increasing the dose up to 10 Discontinue REMICADE if a patient develops a serious infection. mg/kg or treating as often as every 4 weeks. Perform test for latent TB; if positive, start treatment for TB prior to Ankylosing Spondylitis (2.6) starting REMICADE. Monitor all patients for active TB during 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks. treatment, even if initial latent TB test is negative. (5.1) Psoriatic Arthritis (2.7) and Plaque Psoriasis (2.8) MALIGNANCY 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor --------------------DOSAGE FORMS AND STRENGTHS---------------------- (TNF) blockers, including REMICADE. 100 mg of lyophilized infliximab in a 20 mL vial for intravenous infusion. (3) Postmarketing cases of fatal hepatosplenic T-cell lymphoma -------------------------------CONTRAINDICATIONS------------------------------ (HSTCL) have been reported in patients treated with TNF blockers REMICADE doses >5 mg/kg in moderate to severe heart failure. (4) including REMICADE. All REMICADE cases were reported in Previous severe hypersensitivity reaction to REMICADE or known patients with Crohn’s disease or ulcerative colitis, the majority of hypersensitivity to inactive components of REMICADE or to any whom were adolescent or young adult males. All had received murine proteins. (4) azathioprine or 6-mercaptopurine concomitantly with REMICADE ---------------------------WARNINGS AND PRECAUTIONS-------------------- at or prior to diagnosis. (5.2) Serious infections – do not give REMICADE during an active infection. -------------------------RECENT MAJOR CHANGES------------------------- If an infection develops, monitor carefully and stop REMICADE if Warnings and Precautions: Malignancies (5.2) 03/2013 infection becomes serious. (5.1) Warnings and Precautions: Concurrent Administration Invasive fungal infections – for patients who develop a systemic illness with other Biological Therapeutics (5.11) 03/2013 on REMICADE, consider empiric antifungal therapy for those who Warnings and Precautions: Live Vaccines/ reside or travel to regions where mycoses are endemic (5.1) Therapeutic Infectious Agents (5.14) 11/2013 Malignancies – the incidence of malignancies including lymphoma was ----------------------------INDICATIONS AND USAGE--------------------------- greater in REMICADE treated patients than in controls. Due to the risk REMICADE is a tumor necrosis factor (TNF) blocker indicated for: of HSTCL carefully assess the risk/benefit especially if the patient has Crohn’s Disease (1.1): Crohn’s disease or ulcerative colitis, is male, and is receiving reducing signs and symptoms and inducing and maintaining clinical azathioprine or 6-mercaptopurine treatment. (5.2) remission in adult patients with moderately to severely active disease Hepatitis B virus reactivation – test for HBV infection before starting who have had an inadequate response to conventional therapy. REMICADE. Monitor HBV carriers during and several months after reducing the number of draining enterocutaneous and rectovaginal therapy. If reactivation occurs, stop REMICADE and begin anti-viral fistulas and maintaining fistula closure in adult patients with fistulizing therapy. (5.3) disease. Hepatotoxicity – rare severe hepatic reactions, some fatal or Pediatric Crohn’s Disease (1.2): necessitating liver transplantation. Stop REMICADE in cases of reducing signs and symptoms and inducing and maintaining clinical jaundice and/or marked liver enzyme elevations. (5.4) remission in pediatric patients with moderately to severely active disease Heart failure –new onset or worsening symptoms may occur. (4, 5.5) who have had an inadequate response to conventional therapy. Cytopenias – advise patients to seek immediate medical attention if Ulcerative Colitis (1.3): signs and symptoms develop, and consider stopping REMICADE. (5.6) reducing signs and symptoms, inducing and maintaining clinical Hypersensitivity – serious infusion reactions including anaphylaxis or remission and mucosal healing, and eliminating corticosteroid use in serum sickness-like reactions may occur. (5.7) adult patients with moderately to severely active disease who have had Demyelinating disease –exacerbation or new onset may occur. (5.8) an inadequate response to conventional therapy. Lupus-like syndrome – stop REMICADE if syndrome develops. (5.13) Pediatric Ulcerative Colitis (1.4): Live vaccines or therapeutic infectious agents – should not be given with reducing signs and symptoms and inducing and maintaining clinical REMICADE. Bring pediatric patients up to date with all vaccinations remission in pediatric patients with moderately to severely active disease prior to initiating REMICADE. (5.14) who have had an inadequate response to conventional therapy. ------------------------------ADVERSE REACTIONS------------------------------ Rheumatoid Arthritis (1.5) in combination with methotrexate: Most common adverse reactions (>10%) – infections (e.g. upper respiratory, reducing signs and symptoms, inhibiting the progression of structural sinusitis, and pharyngitis), infusion-related reactions, headache, and damage, and improving physical function in patients with moderately to abdominal pain. (6.1) severely active disease. To report SUSPECTED ADVERSE REACTIONS, contact Janssen Ankylosing Spondylitis (1.6): Biotech, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA- reducing signs and symptoms in patients with active disease. 1088 or www.fda.gov/medwatch. Psoriatic Arthritis (1.7): reducing signs and symptoms of active arthritis, inhibiting the ---------------------------------DRUG INTERACTIONS---------------------------- progression of structural damage, and improving physical function. Use with anakinra or abatacept– increased risk of serious infections (7.1) Plaque Psoriasis (1.8): -----------------------USE IN SPECIFIC POPULATIONS----------------------- treatment of adult patients with chronic severe (i.e., extensive and /or Pediatric Use –REMICADE has not been studied in children with disabling) plaque psoriasis who are candidates for systemic therapy and Crohn’s disease or ulcerative colitis<6 years of age. (8.4) when other systemic therapies are medically less appropriate. See 17 for PATIENT COUNSELING INFORMATION and -----------------------DOSAGE AND ADMINISTRATION----------------------- MEDICATION GUIDE. Revised: November 2013 1 Reference ID: 3403013 FULL PRESCRIBING INFORMATION: CONTENTS* 5.14 Live Vaccines/Therapeutic Infectious Agents 6 ADVERSE REACTIONS WARNING: SERIOUS INFECTIONS AND MALIGNANCY 6.1 Clinical Trials Experience 1 INDICATIONS AND USAGE 6.2 Post-marketing Experience 1.1 Crohn’s Disease 7 DRUG INTERACTIONS 1.2 Pediatric Crohn’s Disease 7.1 Use with Anakinra or Abatacept 1.3 Ulcerative Colitis 7.2 Use with Tocilizumab 1.4 Pediatric Ulcerative Colitis 7.3 Use with Other Biological Therapeutics 1.5 Rheumatoid Arthritis 7.4 Methotrexate (MTX) and Other Concomitant Medications 1.6 Ankylosing Spondylitis 7.5 Immunosuppressants 1.7 Psoriatic Arthritis 7.6 Cytochrome P450 Substrates 1.8 Plaque Psoriasis 7.7 Live Vaccines/Therapeutic Infectious Agents 2 DOSAGE AND ADMINISTRATION 8 USE IN SPECIFIC POPULATIONS 2.1 Crohn’s Disease 8.1 Pregnancy 2.2 Pediatric Crohn’s Disease 8.3 Nursing Mothers 2.3 Ulcerative Colitis 8.4 Pediatric Use 2.4 Pediatric Ulcerative Colitis 8.5 Geriatric Use 2.5 Rheumatoid Arthritis 10 OVERDOSAGE 2.6 Ankylosing Spondylitis 11 DESCRIPTION 2.7 Psoriatic Arthritis 12 CLINICAL PHARMACOLOGY 2.8 Plaque Psoriasis 12.1 Mechanism of Action 2.9 Monitoring to Assess Safety 12.2 Pharmacodynamics 2.10 Administration Instructions Regarding Infusion Reactions 12.3 Pharmacokinetics 2.11 General Considerations and Instructions for Preparation and 13 NONCLINICAL TOXICOLOGY Administration 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 3 DOSAGE FORMS AND STRENGTHS 14 CLINICAL STUDIES 4 CONTRAINDICATIONS 14.1 Crohn’s Disease 5 WARNINGS AND PRECAUTIONS (see Boxed WARNINGS) 14.2 Pediatric Crohn’s Disease 5.1 Serious Infections 14.3 Ulcerative Colitis 5.2 Malignancies 14.4 Pediatric Ulcerative Colitis 5.3
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Australian Public Assessment Report for Abatacept (Rch)
    Australian Public Assessment Report for Abatacept (rch) Proprietary Product Name: Orencia Sponsor: Bristol-Myers Squibb Australia Pty Ltd June 2011 About the Therapeutic Goods Administration (TGA) · The TGA is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. · TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Infliximab, Adalimumab and Golimumab for Treating Moderately
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 20 ISSUE 39 MAY 2016 ISSN 1366-5278 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo and Sami Hoque DOI 10.3310/hta20390 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Rachel Archer,1* Paul Tappenden,1 Shijie Ren,1 Marrissa Martyn-St James,1 Rebecca Harvey,1 Hasan Basarir,1 John Stevens,1 Christopher Carroll,1 Anna Cantrell,1 Alan Lobo2 and Sami Hoque3 1Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK 2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK 3Barts Health NHS Trust, London, UK *Corresponding author Declared competing interests of authors: none Published May 2016 DOI: 10.3310/hta20390 This report should be referenced as follows: Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20(39). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Download (PDF)
    Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Information for the public Published: TBC nice.org.uk What has NICE said? Abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) are recommended as possible treatments for people with polyarticular juvenile idiopathic arthritis. Adalimumab and etanercept are recommended as possible treatments for people with enthesitis- related juvenile idiopathic arthritis. Etanercept is recommended as a possible treatment for people with psoriatic juvenile idiopathic arthritis. What does this mean? If your (or your child's) doctor thinks that abatacept, adalimumab, etanercept or tocilizumab are the right treatment, you (or your child) should be able to have the treatment on the NHS. Abatacept, adalimumab, etanercept and tocilizumab should be available on the NHS within 3 months of the guidance being issued. If you (or your child) are not eligible for treatment as described above, you (or your child) should be able to continue taking abatacept, adalimumab, etanercept or tocilizumab until you and your (or your child's) doctor decide it is the right time to stop. © NICE TBC. All rights reserved. Page 1 of 3 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Why has NICE said this? NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS. Abatacept, adalimumab, etanercept and tocilizumab were recommended because the benefits to patients justify their cost. The condition and the treatments Arthritis causes pain and inflammation in joints. Juvenile idiopathic arthritis is a type of arthritis that starts in people younger than 16 years (juvenile).
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Re-Treatment with Abatacept Plus Methotrexate for Disease Flare After Complete Treatment Withdrawal in Patients with Early Rheum
    Rheumatoid arthritis RMD Open: first published as 10.1136/rmdopen-2018-000840 on 8 February 2019. Downloaded from ORIGINAL ARTICLE Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study Paul Emery,1,2 Gerd R Burmester,3 Vivian P Bykerk,4 Bernard G Combe,5 Daniel E Furst,6 Michael A Maldonado,7 Tom WJ Huizinga8 To cite: Emery P, Burmester GR, ABSTRACT Bykerk VP, et al. Re- Objectives To complete reporting of outcomes after total Key messages treatment with abatacept withdrawal of all rheumatoid arthritis (RA) therapy and re- plus methotrexate for disease treatment after flare inA ssessing Very Early Rheumatoid What is already known about this subject? flare after complete treatment arthritis Treatment study (NCT01142726). ► Abatacept in combination with methotrexate induc- withdrawal in patients with es remission more often than methotrexate alone early rheumatoid arthritis: Methods Patients with early RA were initially randomised to double-blind, weekly subcutaneous abatacept plus after 12 months of treatment, with a greater propor- 2-year results from the tion of patients with rheumatoid arthritis (RA) main- AVERT study. methotrexate, or abatacept or methotrexate monotherapy. RMD Open taining remission over 6 months following treatment 2019;5:e000840. doi:10.1136/ At month 12, patients with Disease Activity Score (DAS)28 rmdopen-2018-000840 C reactive protein (CRP) <3.2 had all RA treatments rapidly withdrawal. withdrawn and were observed for ≤12 months or until What does this study add? flare.A fter ≥3 months’ withdrawal, patients with protocol- ► Prepublication history and ► These final results of theA ssessing Very Early additional material for this defined RA flare received open-label abatacept plus Rheumatoid arthritis Treatment (AVERT) study paper are available in online.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]
  • Infliximab Infusion (Page 1 of 2)
    Patient Name: _________________ Provider Orders for: DOB: ________________ InFLIXimab Infusion (Page 1 of 2) = must check off to order / automatically initiated unless crossed out Date: ____________ Time: _________ Weight _______kg Height: _______cm BSA: __________ Diagnosis: Crohn’s disease Ulcerative colitis Plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ankylosing spondylitis PPD Date: ____________ Result: __________ Chest X-Ray Date: _______ Result: __________ Infusion: Inflectra (Drug of choice) Remicade (Non-formulary – Provider must complete a formulary request form) Infusion Frequency: One time only Three visits (Day 0, 2 Weeks, 6 Weeks) Maintenance infusion every _____ weeks until _______ (STOP DATE) Vital Signs: Prior to infusion, at every rate increase, and completion Notify Physician if: Systolic BP less than 90 mmHg or greater than 160 mmHg and/or Pulse less than 60/minute or greater than 120/minute and/or Temperature greater than 38.3 C (101 F) For reactions to inFLIXimab STOP INFUSION and initiate Anaphylactic Reaction Med-Induced Physician Orders – (Form #83EANAPX) Supportive Medications: acetaminophen (Tylenol) 650 mg PO Before inFLIXimab dexamethasone (Decadron) 10 mg or 20 mg IVPB or PO Before inFLIXimab diphenhydrAMINE (Benadryl) 25 mg or 50 mg IVPB or PO Before inFLIXimab Other Medications: __________________________________________________________ ___________________________________________________________________________ IV Line Patency Maintenance: NS IV 250 mL at 30 mL/hr during infusion Flush
    [Show full text]
  • NULOJIX, Through the Centralised Procedure Falling Within the Article 3(1) and Point 1 of Annex of Regulation (EC) No 726/2004
    Assessment report NULOJIX International Nonproprietary Name: Belatacept Procedure No. EMEA/H/C/2098 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 4 1.1. Submission of the dossier.................................................................................... 4 1.2. Steps taken for the assessment of the product ....................................................... 4 2. Scientific discussion ................................................................................ 5 2.1. Introduction ...................................................................................................... 5 2.2. Quality aspects .................................................................................................. 7 2.3. Non-clinical aspects .......................................................................................... 12 Methods of analysis ................................................................................................ 17 Absorption............................................................................................................. 18 Distribution...........................................................................................................
    [Show full text]
  • CIRCULAR 73 of 2015: Entry and Verification (E&V) Criteria for Identifying Beneficiaries with Risk Factors in Medical Scheme
    CIRCULAR Reference: E&V version 9.1 Contact person: Carrie-Anne Cairncross Tel: 012 431 0412 Fax: 086 687 3979 E-mail: [email protected] Date: 11 December 2015 CIRCULAR 73 OF 2015: Entry and verification (E&V) criteria for identifying beneficiaries with risk factors in medical schemes The Council for Medical schemes (CMS) has published the guidelines for identifying medical scheme beneficiaries with risk factors in accordance with the entry and verification criteria. (http://www.medicalschemes.com/files/ITAP%20Documents/Vers9_1OfEVGdlns20151211.pdf) It is important that medical schemes and administrators take note of the updated version 9.1 and implement all the changes made in the guideline before they extract the data for the 2015 submission. The changes are listed below. 1. Parts 3 and 4, which relate to preparation and submission of data has been amended to reflect the submission of Scheme Risk Measurement (SRM) data via the Healthcare Utilisation Annual Statutory Returns (ASR) System. 2. Changes to clinical entry end verification criteria: 2.1. The provider type was changed from any registered medical practitioner to specialist ophthalmologist (Table 17) 2.2. Glaucoma was added to the list of conditions that need specialist diagnosis as stated in paragraph 5.17 2.3. Rheumatoid Arthritis was removed from paragraph 5.17 2.4. The note on the Rheumatoid Arthritis table i.e. “Where a patient is not using disease modifying anti-rheumatic medicines, the diagnosis must be verified by a specialist physician or rheumatologist” has been updated to state “Where a patient is using disease modifying anti-rheumatic medicines, the diagnosis must be verified by a specialist physician or rheumatologist.” 2.5.
    [Show full text]
  • Active Conventional Treatment and Three Different Biological Treatments in Early Rheumatoid Arthritis
    BMJ: first published as 10.1136/bmj.m4328 on 2 December 2020. Downloaded from RESEARCH Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial Merete Lund Hetland,1,2 Espen A Haavardsholm,3 Anna Rudin,4,5 Dan Nordström,6,7 Michael Nurmohamed,8,9 Bjorn Gudbjornsson,10,11 Jon Lampa,12 Kim Hørslev-Petersen,13,14 Till Uhlig,3,15 Gerdur Grondal,10,11 Mikkel Østergaard,1,2 Marte S Heiberg,3 Jos Twisk,16 Kristina Lend,12 Simon Krabbe,1,2 Lise Hejl Hyldstrup,1,2 Joakim Lindqvist,12 Anna-Karin Hultgård Ekwall,4,5 Kathrine Lederballe Grøn,1 Meliha Kapetanovic,17 Francesca Faustini,12 Riitta Tuompo,6,7 Tove Lorenzen,18 Giovanni Cagnotto,19,20 Eva Baecklund,21 Oliver Hendricks,13 Daisy Vedder,8 Tuulikki Sokka-Isler,22 Tomas Husmark,23 Maud-Kristine Aga Ljoså,24 Eli Brodin,25 Torkell Ellingsen,26 Annika Söderbergh,27 Milad Rizk,28 Åsa Reckner Olsson,29 Per Larsson,30 Line Uhrenholt,31 Søren Andreas Just,32 David John Stevens,33 Trine Bay Laurberg,34 Gunnstein Bakland,35 Inge C Olsen,36 Ronald van Vollenhoven,9,12 on behalf of the NORD-STAR study group For numbered affiliations see ABSTRACT and rheumatoid factor or anti-citrullinated protein end of the article. OBJECTIVE antibody positivity, or increased C reactive protein. Correspondence to: To evaluate and compare benefits and harms of three INTERVENTIONS M L Hetland biological treatments with different modes of action Randomised 1:1:1:1, stratified by country, sex, Copenhagen Center for versus active conventional treatment in patients with Arthritis Research, Center and anti-citrullinated protein antibody status.
    [Show full text]